LGMD

Vita Therapeutics Bolsters Leadership to Advance Multiple Technology Platforms

Retrieved on: 
Tuesday, March 22, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Therapy, Regenerative medicine, Quality assurance, Biomedical sciences, Biotechnology, Neurodegeneration, Champions Oncology, University of Pittsburgh School of Medicine, Technology, Knowledge, Bankers Trust, Series, GMP, University, MANA, Johns Hopkins University, IPSC, Quality, Cell engineering, CMC, Faculty, Senior, Industry, B cell, Cancer, Certification, University of Washington Department of Bioengineering, Clinical trial, Genetics, Doctor of Philosophy, ASCP, Organizational culture, Vita, Xana, Manufacturing, Health technology, MS, Trust, StemCells, Inc., Wilfrid Sellars, Patient, Company, Muscular dystrophy, Organization, Precigen, Leadership, Microbiology, Technology transfer, BS, Food, US Foods, Regulation, Mesoblast, Translational research, LGMD, Management, Pharmaceutical industry, Research

In addition, Brown Advisory Chief Financial Officer and Chief Operating Officer David M. Churchill is newly-appointed to the Vita Therapeutics Board of Directors.

Key Points: 
  • In addition, Brown Advisory Chief Financial Officer and Chief Operating Officer David M. Churchill is newly-appointed to the Vita Therapeutics Board of Directors.
  • His leadership roles at Brown Advisory will serve our company well as he provides knowledge and perspective around our growing infrastructure.
  • Vita Therapeutics is a biotechnology company generating state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers.
  • Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients.

Atamyo Therapeutics Reaches Significant Regulatory and Financial Milestones for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, Genetics, Health, Clinical Trials, Orphan drug, Orphan, MHRA, European Medicines Agency, AAV, FKRP, Therapy, CNRS, Muscular dystrophy, Review, Investor, Lists of diseases, Food, Degenerative disease, Health care, FDA, Life, US Foods, EMA, Patient, CTA, Weakness, CEO, Research, LGMD, Pharmaceutical industry, Vaccine, Biotechnology, Genetics, Health, Clinical Trials

Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, today announced multiple major regulatory and financial milestones for ATA-100, a one-time gene therapy for the treatment of fukutin-related protein (FKRP) limb-girdle muscular dystrophy Type 2I/R9 (LGMD2I/R9).

Key Points: 
  • Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, today announced multiple major regulatory and financial milestones for ATA-100, a one-time gene therapy for the treatment of fukutin-related protein (FKRP) limb-girdle muscular dystrophy Type 2I/R9 (LGMD2I/R9).
  • ATA-100, a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.

Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9

Retrieved on: 
Monday, December 6, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Patient, Weakness, Muscular dystrophy, CEO, Degenerative disease, Biomarker, Health care, MHRA, CTAS, LGMD, Research, CNRS, Motivation, AAV, FKRP, CTA, Therapy, National Hospital Organization Nagara Medical Center, Lists of diseases, Life, Pathology, Newcastle University, Pharmaceutical industry, Dentistry

Atamyo plans to initiate dosing in patients for ATA-100 in the first half of 2022.

Key Points: 
  • Atamyo plans to initiate dosing in patients for ATA-100 in the first half of 2022.
  • ATA-100, a gene therapy candidate for LGMD21/R9, delivers a normal copy of the gene for production of FKRP proteins.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.

Nyheim Hines of the Indianapolis Colts to Wear Cleats for Muscular Dystrophy Association on Game Day Sunday, December 5

Retrieved on: 
Tuesday, November 30, 2021
Research, Instagram, Dolphin, AFL, Disability, Neuromuscular disease, Firefighter, Disease, ALS, National Sexual Violence Resource Center, International Association, Partnership, Awareness, Muscular Dystrophy Association, Indianapolis Colts, International Association of Fire Fighters, Degenerative disease, MDA, COVID-19, Muscular dystrophy, LGMD, Indianapolis, Twitter, View, NFL, Federation, Boot, Organization, PSAS, National Football League, Social media, Science, Multimedia, Drug development, Giant, Association, Hines, Pharmaceutical industry

Players from across the NFL have supported the Muscular Dystrophy Association (MDA), and Nyheim Hines, 2021 MDA National Spokesperson, and running back for the Indianapolis Colts will be wearing his cleats for MDA on game day, Sunday, December 5 for Colts vs Texans.

Key Points: 
  • Players from across the NFL have supported the Muscular Dystrophy Association (MDA), and Nyheim Hines, 2021 MDA National Spokesperson, and running back for the Indianapolis Colts will be wearing his cleats for MDA on game day, Sunday, December 5 for Colts vs Texans.
  • NFL's My Cause My Cleats charitable campaign features cleats raising awareness for Muscular Dystrophy Association.
  • Pictured: Cleats Nyheim Hines of the Indianapolis Colts will be wearing Dec. 5 game day.
  • "Raising awareness for the Muscular Dystrophy Association is important to me because I have seen my mother, grandmother and uncle live with a neuromuscular disease," said Indianapolis Colts running back Hines.

Atamyo Therapeutics Submits CTA in Europe for ATA-100, Its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9

Retrieved on: 
Tuesday, October 26, 2021
Other Health, Radiology, Pharmaceutical, Research, Oncology, Infectious Diseases, Genetics, Stem Cells, Science, Practice Management, Veterinary, Clinical Trials, Managed Care, Cardiology, FDA, Biotechnology, Surgery, Health, Safety, Science, Research, Entrepreneurship, Hospital, Gene, Degenerative disease, Industry, European Medicines Agency, Pathology, File, Patient, Lists of diseases, Achievement, LGMD, Life, Muscular dystrophy, FKRP, CEO, Biomarker, CTA, Program, Weakness, Therapy, CNRS, Lysogen, AAV, Pharmaceutical industry, Medical device

The company is leveraging Genethons unique expertise in AAV-based gene therapy, muscular dystrophies and breakthrough technologies for the safety and efficacy of AAV-based gene therapies.

Key Points: 
  • The company is leveraging Genethons unique expertise in AAV-based gene therapy, muscular dystrophies and breakthrough technologies for the safety and efficacy of AAV-based gene therapies.
  • The creation of Atamyo by Genethon stems from its ambition to create a leader of gene therapy applied to LGMDs.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.

Muscular Dystrophy Association Kicks Off National Muscular Dystrophy Awareness Month Announcing Access Survey Data, Community Education, and Events

Retrieved on: 
Monday, August 30, 2021
Muscular Dystrophy Association, Employment, ALS, Twitter, Fill Your Boots, City, Muscular dystrophy, International Association, Community education, Insurance, Social media, Degenerative disease, Boot, MDA, Las Vegas Aviators, PSA, Research, IAFF, Doctor of Philosophy, PSAS, Crowd control, Awareness, Neuromuscular disease, International Association of Fire Fighters, Partnership, Caregiver, CEO, Education, VP, Disability, LGMD, FDA, Raider, Firefighter, Air travel, Public relations, Pharmaceutical industry

"We're proud of the extensive campaign we are launching in September to elevate awareness of people living with neuromuscular diseases.

Key Points: 
  • "We're proud of the extensive campaign we are launching in September to elevate awareness of people living with neuromuscular diseases.
  • "We use this survey to gauge how our community is navigating changes in everything from medical reimbursements to education advancements.
  • Hines' mother lives with limb-girdle muscular dystrophy (LGMD), and is included in the video and audio PSAs, available for media here , through the end of 2021.
  • Throughout the month of September, MDA will continue advocacy initiatives from newborn screening to access to healthcare, education, accessible air travel, employment and more.

Muscular Dystrophy Association Announces Its Inaugural MDA Takes Vegas Stream-a-thon Labor Day Weekend

Retrieved on: 
Thursday, August 26, 2021
Muscular Dystrophy Association, ALS, Carnival Corporation & plc, Twitter, Muscular dystrophy, International Association, Labour, Federation, Degenerative disease, Science, MDA, Las Vegas Aviators, Research, Pokémon, Crowd control, Awareness, Multimedia, Neuromuscular disease, National Sexual Violence Resource Center, NFL, International Association of Fire Fighters, Indianapolis, Indianapolis Colts, Disability, LGMD, Raider, COVID-19, Firefighter, View, Play, Drug development, Casino, Video game

Building on MDA's legacy in Las Vegas, the organization is recapturing its Labor Day prominence with the MDA Takes Vegas event, which will harness the power of gaming and streaming, upping the stakes with a must-see, must-play production from Las Vegas on September 4 from 4:00 p.m. to midnight ET.

Key Points: 
  • Building on MDA's legacy in Las Vegas, the organization is recapturing its Labor Day prominence with the MDA Takes Vegas event, which will harness the power of gaming and streaming, upping the stakes with a must-see, must-play production from Las Vegas on September 4 from 4:00 p.m. to midnight ET.
  • Building on its innovative fundraising roots, MDA brings together its heritage with exciting new gaming platforms that are core to the MDA community.
  • The MDA Takes Vegas stream-a-thon supports MDA's mission of empowering people living with neuromuscular diseases to achieve their full potential.
  • For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.